Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Carrasco-Sánchez FJ
- Carretero-Anibarro E
- Gargallo MÁ
- Gómez-Huelgas R
- Orozco-Beltrán D
- Pines Corrales PJ
- Ruiz Quintero MA
Grupos
Abstract
BACKGROUND: This consensus aims to clarify the role of Dipeptidyl Peptidase-4 inhibitors (iDPP-4) in managing patients with diabetes during the COVID-19 pandemic. MATERIALS AND METHODS: A PubMed bibliographic search was carried out (December 2019-February 2021). Oxford methodology was used for the evaluation of evidence and possible recommendations were established by consensus. RESULTS: Diabetes appears to be an independent factor in COVID-19 disease (evidence 2b). No increased risk of contagion with iDPP-4 is demonstrated (evidence 2b), and its use has been shown to be safe (evidence 2b). The use of this drug may present a specific benefit in reducing mortality, particularly in in-hospital use (evidence 2a), reducing admission to intensive care units (evidence 2b) and the need for mechanical ventilation (evidence 2b). CONCLUSIONS: The use of iDPP-4 appears to be safe in patients with COVID-19, and quality studies are needed to clarify their possible advantages further.
Copyright © 2021 SEEN and SED. Published by Elsevier España, S.L.U. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 2530-0180, 2530-0180
- Tipo:
- Article
- Páginas:
- 209-218
- PubMed:
- 35353681
Endocrinologia Diabetes y Nutricion ELSEVIER
Documentos
- No hay documentos
Filiaciones
Keywords
- Antidiabetic drugs; COVID-19; Diabetes; Fármacos antidiabéticos; Mortalidad; Mortality; iDPP-4
Cita
Carrasco FJ,Carretero E,Gargallo MÁ,Gómez R,MERINO JF,Orozco D,Pines PJ,Ruiz MA. Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19. Endocrinol. Diabetes Nutr. 2022. 69. (3):p. 209-218. IF:1,900. (4).
Portal de investigación